305 related articles for article (PubMed ID: 31597607)
1. Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.
Chen Z; Yu Y; Cai J; Li H
Trends Endocrinol Metab; 2019 Dec; 30(12):903-914. PubMed ID: 31597607
[TBL] [Abstract][Full Text] [Related]
2. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
Cai J; Zhang XJ; Li H
Trends Endocrinol Metab; 2018 Oct; 29(10):712-722. PubMed ID: 30131212
[TBL] [Abstract][Full Text] [Related]
3. Innate immune regulatory networks in hepatic lipid metabolism.
Bai L; Li H
J Mol Med (Berl); 2019 May; 97(5):593-604. PubMed ID: 30891617
[TBL] [Abstract][Full Text] [Related]
4. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
[TBL] [Abstract][Full Text] [Related]
5. Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.
Cai J; Xu M; Zhang X; Li H
Annu Rev Pathol; 2019 Jan; 14():153-184. PubMed ID: 30230967
[TBL] [Abstract][Full Text] [Related]
6. Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer.
Cheng C; Zhuo S; Zhang B; Zhao X; Liu Y; Liao C; Quan J; Li Z; Bode AM; Cao Y; Luo X
Int J Biol Sci; 2019; 15(8):1654-1663. PubMed ID: 31360108
[TBL] [Abstract][Full Text] [Related]
7. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease.
Chen Z; Tian R; She Z; Cai J; Li H
Free Radic Biol Med; 2020 May; 152():116-141. PubMed ID: 32156524
[TBL] [Abstract][Full Text] [Related]
8. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease.
Arias-Loste MT; Fábrega E; López-Hoyos M; Crespo J
Biomed Res Int; 2015; 2015():319745. PubMed ID: 26491664
[TBL] [Abstract][Full Text] [Related]
9. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
Bibbò S; Ianiro G; Dore MP; Simonelli C; Newton EE; Cammarota G
Mediators Inflamm; 2018; 2018():9321643. PubMed ID: 29563854
[TBL] [Abstract][Full Text] [Related]
10. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
11. Macrophages in the pathophysiology of NAFLD: The role of sex differences.
Ministrini S; Montecucco F; Sahebkar A; Carbone F
Eur J Clin Invest; 2020 Jun; 50(6):e13236. PubMed ID: 32294235
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
13. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
14. The regulation of TFEB in lipid homeostasis of non-alcoholic fatty liver disease: Molecular mechanism and promising therapeutic targets.
Yu S; Wang Z; Ding L; Yang L
Life Sci; 2020 Apr; 246():117418. PubMed ID: 32057899
[TBL] [Abstract][Full Text] [Related]
15. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
16. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling.
Giles DA; Moreno-Fernandez ME; Stankiewicz TE; Graspeuntner S; Cappelletti M; Wu D; Mukherjee R; Chan CC; Lawson MJ; Klarquist J; Sünderhauf A; Softic S; Kahn CR; Stemmer K; Iwakura Y; Aronow BJ; Karns R; Steinbrecher KA; Karp CL; Sheridan R; Shanmukhappa SK; Reynaud D; Haslam DB; Sina C; Rupp J; Hogan SP; Divanovic S
Nat Med; 2017 Jul; 23(7):829-838. PubMed ID: 28604704
[TBL] [Abstract][Full Text] [Related]
17. Metabolic aspects of adult patients with nonalcoholic fatty liver disease.
Abenavoli L; Milic N; Di Renzo L; Preveden T; Medić-Stojanoska M; De Lorenzo A
World J Gastroenterol; 2016 Aug; 22(31):7006-16. PubMed ID: 27610012
[TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease.
Carranza-Trejo AM; Vetvicka V; Vistejnova L; Kralickova M; Montufar EB
Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):783-796. PubMed ID: 33557653
[No Abstract] [Full Text] [Related]
20. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
Lim S; Taskinen MR; Borén J
Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
